Sanofi ends program after NSCLC Phase 3 trial did not meet primary endpoint

 Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

• CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
• Sanofi reinforces commitment to broader oncology development program including CEACAM5-directed antibody drug conjugates (ADC) with additional anticipated trials

https://www.biospace.com/article/releases/press-release-sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-2l-nsclc-phase-3-trial-did-not-meet-a-primary-endpoint/